CAMBRIDGE, MA –November 10, 2020 – Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020.
Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET.
Caraway’s President and Chief Scientific Officer, Magdalene Moran, Ph.D., will present in two sessions at the Autophagy Showcase at the Drugging Autophagy Summit on November 19th. Dr. Moran will moderate and participate in the panel discussion titled, ‘How Much is Our Understanding of the Fundamental Biology Impacting the Druggability of Autophagy?’ on November 19, 2020 at 10:05am ET and will deliver a presentation titled, ‘Targeting TRPML1 for Neurodegenerative Disease’ on November 19, 2020 at 11:05am ET. For more information about the Drugging Autophagy Summit visit https://www.druggingautophagy.com/.
“At Caraway we are developing an approach to combine genetic data and our unique understanding of lysosomal function to discover small molecules that activate a cell’s clean-up and recycling processes thereby accelerating clearance of toxic materials and defective cellular components,” said Martin D. Williams, Chief Executive Officer of Caraway Therapeutics. “Magdalene and I are pleased to continue to showcase this targeted approach and the importance of modulating lysosomal function as a therapeutic strategy at the Stifel Banking Conference and Drugging Autophagy Summit.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caroline Rufo, PhD or Kari Watson
email@example.com or firstname.lastname@example.org